Next generation: tuberculosis vaccines that elicit protective CD8+ T cells.
Tuberculosis continues to cause considerable human morbidity and mortality worldwide, particularly in people coinfected with HIV. The emergence of multidrug resistance makes the medical treatment of tuberculosis even more difficult. Thus, the development of a tuberculosis vaccine is a global health priority. Here we review the data concerning the role of CD8+ T cells in immunity to tuberculosis and consider how CD8+ T cells can be elicited by vaccination. Many immunization strategies have the potential to elicit CD8+ T cells and we critically review the data supporting a role for vaccine-induced CD8+ T cells in protective immunity. The synergy between CD4+ and CD8+ T cells suggests that a vaccine that elicits both T-cell subsets has the best chance at preventing tuberculosis.
Behar
Samuel M
SM
Brigham and Women's Hospital and Harvard Medical School, Division of Rheumatology, Immunology and Allergy, Smith Building, Room 516C, One Jimmy Fund Way, Boston, MA 02115, USA. sbehar@rics.bwh.harvard.edu
Woodworth
Joshua S M
JS
Wu
Ying
Y
D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D015658:HIV Infections / Q000150:complications; D006801:Humans; D014376:Tuberculosis / Q000276:immunology / Q000517:prevention & control*; D032581:Tuberculosis Vaccines / Q000276:immunology*; D019444:Vaccines, DNA / Q000276:immunology; D022223:Vaccines, Subunit / Q000276:immunology
D032581:Tuberculosis Vaccines; D019444:Vaccines, DNA; D022223:Vaccines, Subunit